ProAxsis Shows Progress with Strategic Fundraise
Deal News | Feb 04, 2025 | EMV Capital
ProAxsis, a portfolio company of EMV Capital, has announced significant financial and operational developments. The company, known for its protease-targeted technology and NEATstik platform, aims to address unmet needs in chronic respiratory disease diagnostics. ProAxsis has increased its revenues while reducing losses, attributed to its robust sales pipeline and provisional orders. The company also has advanced plans for a clinical study in Chronic Obstructive Pulmonary Disease (COPD) in collaboration with Imperial College London to expand clinical trial work. ProAxsis continues to benefit from grant funding. EMV Capital has played a crucial role in the company's progression through its value creation services, enhancing ProAxsis's business focus and positioning it well for future growth opportunities. The CEO of EMV Capital, Ilian Iliev, highlighted ProAxsis's progress in 2024, with a current fundraise to support critical clinical milestones and commercial growth.
Sectors
- Biotechnology
- Healthcare
- Investment Management
Geography
- United Kingdom – ProAxsis is collaborating with Imperial College London, indicating a primary geographical focus in the UK.
Industry
- Biotechnology – ProAxsis operates within the biotechnology sector with a focus on protease-targeted technology for respiratory disease diagnostics.
- Healthcare – ProAxsis is involved in advancing healthcare solutions by addressing unmet needs in chronic respiratory diseases, particularly COPD.
- Investment Management – EMV Capital, a PE firm, is involved in managing and supporting investment in ProAxsis, positioning itself within the investment management sector.
Financials
- N/A – The article discusses a proposed fundraise to support clinical milestones and commercialisation but does not specify the financial amount.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ProAxsis | Target Company | Company | A biotechnology company developing protease-targeted technology for respiratory disease diagnostics. |
| EMV Capital | Private Equity Firm | Company | A private equity firm providing investment and value creation services to portfolio companies like ProAxsis. |
| Imperial College London | Clinical Partner | Institution | A leading academic institution partnering with ProAxsis for clinical studies in COPD. |
| Ilian Iliev | CEO of EMV Capital | Person | CEO of EMV Capital, providing strategic oversight and support to portfolio companies like ProAxsis. |